INT13510

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 1991
Last Reported 2011
Negated 21
Speculated 10
Reported most in Body
Documents 530
Total Number 541
Disease Relevance 405.68
Pain Relevance 16.79

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (ERBB2) signal transduction (ERBB2) plasma membrane (ERBB2)
nucleus (ERBB2) cytoplasm (ERBB2)
Anatomy Link Frequency
MCF-7 7
lymph node 7
node 4
axillary 3
brain 3
ERBB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 2162 100.00 Very High Very High Very High
agonist 83 99.30 Very High Very High Very High
Central nervous system 767 99.16 Very High Very High Very High
methotrexate 184 99.04 Very High Very High Very High
Chronic pancreatitis 26 98.76 Very High Very High Very High
palliative 327 98.68 Very High Very High Very High
Angina 29 97.94 Very High Very High Very High
intrathecal 19 97.90 Very High Very High Very High
cytokine 169 97.16 Very High Very High Very High
Kinase C 46 96.56 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cancer 22995 100.00 Very High Very High Very High
Breast Cancer 16054 100.00 Very High Very High Very High
Disease 5749 100.00 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 4199 100.00 Very High Very High Very High
INFLAMMATION 2072 100.00 Very High Very High Very High
Targeted Disruption 439 100.00 Very High Very High Very High
Metastasis 3284 99.98 Very High Very High Very High
Carcinoma 1404 99.98 Very High Very High Very High
Stomach Cancer 1298 99.98 Very High Very High Very High
Ovarian Cancer 656 99.96 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pivotal trials in breast cancer showed that it has activity as a single agent in a subset of patients whose tumors greatly over-express HER2, but results were even more impressive when it was used in combination with chemotherapy.
Gene_expression (over) of HER2 associated with cancer and breast cancer
1) Confidence 0.78 Published 1999 Journal Cancer Biother. Radiopharm. Section Abstract Doc Link 10850281 Disease Relevance 0.53 Pain Relevance 0
It should also prove to be useful in the treatment of subsets of patients with other adenocarcinomas whose tumors over-express HER2.
Gene_expression (over) of HER2 associated with adenocarcinoma and cancer
2) Confidence 0.78 Published 1999 Journal Cancer Biother. Radiopharm. Section Abstract Doc Link 10850281 Disease Relevance 0.69 Pain Relevance 0
Trastuzumab is a recombinant humanised monoclonal antibody specific for the growth factor receptor p185(HER2) (HER2) which is overexpressed in 25 to 30% of breast cancer tumours.
Gene_expression (overexpressed) of HER2 associated with cancer and breast cancer
3) Confidence 0.78 Published 1999 Journal BioDrugs Section Abstract Doc Link 18031170 Disease Relevance 0.50 Pain Relevance 0.04
The drug inhibits the growth of human breast cancer cells overexpressing HER2 in vitro and in vivo.
Gene_expression (overexpressing) of HER2 associated with breast cancer
4) Confidence 0.78 Published 1999 Journal BioDrugs Section Abstract Doc Link 18031170 Disease Relevance 0.58 Pain Relevance 0.04
In patients with metastatic breast cancer whose tumours overexpressed HER2, trastuzumab (4 mg/kg loading dose then 2 mg/kg/week by intravenous infusion) produced objective responses in 21% of 213 patients.
Gene_expression (overexpressed) of HER2 associated with cancer and advanced or metastatic breast cancer
5) Confidence 0.78 Published 1999 Journal BioDrugs Section Abstract Doc Link 18031170 Disease Relevance 0.67 Pain Relevance 0.05
Trastuzumab is a recombinant humanised monoclonal antibody specific for the growth factor receptor p185(HER2) (HER2) which is overexpressed in 25 to 30% of breast cancer tumours.
Gene_expression (overexpressed) of HER2 associated with cancer and breast cancer
6) Confidence 0.78 Published 1999 Journal BioDrugs Section Abstract Doc Link 18031170 Disease Relevance 0.50 Pain Relevance 0.04
Trastuzumab has been approved by the US Food and Drug Administration as a single agent for the treatment of patients who have metastatic breast cancer involving overexpression of the HER2 protein and who have received 1 or more chemotherapy regimens; in combination with paclitaxel, it has been approved for the treatment of such patients who have not received chemotherapy.
Gene_expression (overexpression) of HER2 protein associated with advanced or metastatic breast cancer
7) Confidence 0.78 Published 1999 Journal Clin Ther Section Abstract Doc Link 10211534 Disease Relevance 1.91 Pain Relevance 0.26
In vitro and in vivo preclinical studies have shown that administration of trastuzumab alone or in combination with paclitaxel or carboplatin significantly inhibits the growth of breast tumor-derived cell lines that overexpress the HER2 gene product.
Gene_expression (overexpress) of HER2 gene associated with breast cancer
8) Confidence 0.78 Published 1999 Journal Clin Ther Section Abstract Doc Link 10211534 Disease Relevance 0.35 Pain Relevance 0
The beneficial effects were greatest in patients with the greatest degree (3+) of HER2 protein overexpression.
Gene_expression (overexpression) of HER2 protein
9) Confidence 0.78 Published 1999 Journal Clin Ther Section Abstract Doc Link 10211534 Disease Relevance 1.12 Pain Relevance 0.12
Studies that specifically analyzed HER2 expression and/or amplification in Barrett's esophagus reported positivity rates of 38–50% and showed an association with progression from Barrett's esophagus to dysplasia and adenocarcinoma [76–79].
Gene_expression (expression) of HER2 in esophagus associated with adenocarcinoma and cleidocranial dysplasia
10) Confidence 0.78 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.68 Pain Relevance 0
In addition, differences between HER2 overexpression in European and Asian/South-American populations (22–28% versus 3–15%, resp.) have been reported by some studies [68], but others have found these differences to be less substantial [69].
Gene_expression (overexpression) of HER2
11) Confidence 0.78 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.94 Pain Relevance 0
The data on HER2 overexpression in esophageal cancer are variable, with most studies showing HER2 overexpression in 9%–60% of cases, whereas other reports failed to observe HER2 expression [72].
Gene_expression (expression) of HER2 associated with esophageal cancer
12) Confidence 0.78 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.30 Pain Relevance 0
With regard to this testing, overexpression of the HER2 protein seems to possess the best predictive value.
Gene_expression (overexpression) of HER2 protein
13) Confidence 0.78 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.86 Pain Relevance 0
The data on HER2 overexpression in esophageal cancer are variable, with most studies showing HER2 overexpression in 9%–60% of cases, whereas other reports failed to observe HER2 expression [72].
Gene_expression (overexpression) of HER2 associated with esophageal cancer
14) Confidence 0.78 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.37 Pain Relevance 0
In breast cancer, it is generally thought that HER2 overexpression is the direct result of gene amplification [59].
Gene_expression (overexpression) of HER2 associated with breast cancer
15) Confidence 0.78 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.66 Pain Relevance 0
Thirdly, although some studies have reported that HER2 amplification and overexpression are highly homogeneous within tumors and between primary and metastatic gastric cancer [62], others have reported significant heterogeneity in both gene amplification and protein overexpression in individual cancers, even among IHC 3+ cancers [67, 86].
Gene_expression (overexpression) of HER2 associated with cancer and stomach cancer
16) Confidence 0.78 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.79 Pain Relevance 0
The reason for the selective overexpression of HER2 in intestinal-type gastric cancers is complex and needs further investigation.
Gene_expression (overexpression) of HER2 associated with stomach cancer
17) Confidence 0.78 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.39 Pain Relevance 0
The relationship between HER2 expression and the prognosis of patients with esophageal cancer is not clear.
Gene_expression (expression) of HER2 associated with esophageal cancer
18) Confidence 0.78 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.49 Pain Relevance 0
Reported rates of HER2 overexpression in gastroesophageal cancer vary widely (2–45%) due to small sample sizes, differences in patient populations and methodological and scoring differences between studies [45, 62–67].
Gene_expression (overexpression) of HER2 associated with cancer
19) Confidence 0.78 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.95 Pain Relevance 0
The data on HER2 overexpression in esophageal cancer are variable, with most studies showing HER2 overexpression in 9%–60% of cases, whereas other reports failed to observe HER2 expression [72].
Gene_expression (overexpression) of HER2 associated with esophageal cancer
20) Confidence 0.78 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 1.29 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox